Company & Sponsor Intelligence
Rush University Medical Center
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials7
Recruiting3
Completed3
Countries1
Therapeutic footprint
autismepilepsyout_of_scopeparkinsons
Indexed studies
NCT06608758End Diagnostic Overshadowing
out_of_scope · United StatesRECRUITING
out_of_scope · United StatesRECRUITING
NCT03336697Determining the Microbiota Composition of the Middle Meatus in Parkinson's
parkinsons · United StatesCOMPLETED
parkinsons · United StatesCOMPLETED
NCT02918864Oxytocin and Social Cognitive Skills Groups
autism · United StatesPHASE2
autism · United StatesPHASE2
NCT03552484In-Home Care for Patients With PSP and Related Disorders
parkinsons · United StatesNA
parkinsons · United StatesNA
NCT01309074Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline
epilepsy · United StatesPHASE4
epilepsy · United StatesPHASE4
NCT07005505Automatic Tube Compensation vs. Pressure Support Ventilation During Spontaneous Breathing Trials in Adults
out_of_scope · United StatesNA
out_of_scope · United StatesNA
NCT05114538Improving the Part C Early Intervention Service Delivery System for Children With ASD
autism · United StatesNA
autism · United StatesNA
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →